Can a new drug ASP388B take on advanced solid tumors?

NCT ID NCT07730021

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in specific tumor types. The main goals are to check safety and look for early signs that the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called ASP388B, given alone or with standard chemotherapies (pembrolizumab, carboplatin, oxaliplatin, 5-fluorouracil)
What this could lead to
If ASP388B proves safe and shows activity, it could offer a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial testing ASP388B for the first time in humans. The drug may cause unexpected side effects, and it is too soon to know whether it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.